EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:BIOC

Biocept - BIOC Stock Forecast, Price & News

$0.76
0.00 (-0.34%)
(As of 11/29/2022 04:14 PM ET)
Add
Compare
Today's Range
$0.74
$0.78
50-Day Range
$0.74
$0.93
52-Week Range
$0.70
$4.40
Volume
43,041 shs
Average Volume
99,736 shs
Market Capitalization
$13.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Biocept MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
441.0% Upside
$4.00 Price Target
Short Interest
Healthy
0.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Biocept in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.66) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

560th out of 1,038 stocks

Medical Laboratories Industry

15th out of 25 stocks

BIOC stock logo

About Biocept (NASDAQ:BIOC) Stock

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Stock News Headlines

StockNews.com Initiates Coverage on Biocept (NASDAQ:BIOC)
Biocept Reports Third Quarter 2022 Financial Results
Biocept (NASDAQ:BIOC) Now Covered by StockNews.com
Biocept Reports Second Quarter 2022 Financial Results
Form 8-K BIOCEPT INC For: Oct 18 - StreetInsider.com
Biocept to Present at the LD Micro Main Event XV
See More Headlines
Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Company Calendar

Last Earnings
11/15/2021
Today
11/29/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOC
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+423.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-2,820,000.00
Pretax Margin
-32.74%

Debt

Sales & Book Value

Annual Sales
$61.25 million
Book Value
$2.23 per share

Miscellaneous

Free Float
16,902,000
Market Cap
$13.03 million
Optionable
Optionable
Beta
0.72

Key Executives

  • Mr. Samuel D. Riccitelli (Age 63)
    Interim Pres, CEO & Chairman
    Comp: $67.24k
  • Mr. Antonino Morales (Age 66)
    Interim CFO & Director
    Comp: $20.76k
  • Dr. Michael C. Dugan M.D. (Age 59)
    Sr. VP, Chief Medical Officer & Medical Director
    Comp: $413.31k
  • Dr. Soon Kap Hahn Ph.D.
    Founder
  • Dr. Philippe J. Marchand Ph.D. (Age 59)
    Chief Operating Officer
  • Mr. Pavel Tsinberg
    Director of Technology Devel.
  • Mr. Darrell Taylor Esq. (Age 57)
    Sr. VP, Chief Legal Officer & Chief Compliance Officer
  • Mr. David S. Moskowitz R.Ph.
    MBA, VP of Strategy & Corp. Communications
  • Mr. Michael Terry (Age 67)
    Sr. VP of Corp. Devel.
  • Antonio Paternostro
    VP of Sales













BIOC Stock - Frequently Asked Questions

Should I buy or sell Biocept stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOC shares.
View BIOC analyst ratings
or view top-rated stocks.

What is Biocept's stock price forecast for 2023?

1 brokerages have issued twelve-month target prices for Biocept's shares. Their BIOC share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 421.9% from the stock's current price.
View analysts price targets for BIOC
or view top-rated stocks among Wall Street analysts.

How have BIOC shares performed in 2022?

Biocept's stock was trading at $3.62 at the beginning of 2022. Since then, BIOC stock has decreased by 78.8% and is now trading at $0.7665.
View the best growth stocks for 2022 here
.

Are investors shorting Biocept?

Biocept saw a decline in short interest in November. As of November 15th, there was short interest totaling 63,500 shares, a decline of 19.2% from the October 31st total of 78,600 shares. Based on an average daily trading volume, of 49,800 shares, the days-to-cover ratio is currently 1.3 days.
View Biocept's Short Interest
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.06. The medical research company had revenue of $17.47 million for the quarter, compared to the consensus estimate of $16.87 million. Biocept had a negative net margin of 32.99% and a negative trailing twelve-month return on equity of 49.18%. During the same quarter in the previous year, the company earned ($0.43) earnings per share.

When did Biocept's stock split?

Biocept shares reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Michael Nall's approval rating as Biocept's CEO?

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.62%). Insiders that own company stock include David F Hale and David F Hale.
View institutional ownership trends
.

How do I buy shares of Biocept?

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.77.

How much money does Biocept make?

Biocept (NASDAQ:BIOC) has a market capitalization of $13.08 million and generates $61.25 million in revenue each year. The medical research company earns $-2,820,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

How many employees does Biocept have?

The company employs 104 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.

This page (NASDAQ:BIOC) was last updated on 11/29/2022 by MarketBeat.com Staff